Weekly Bendamustine and Bortezomib Combination Therapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or B-CLL: A Single-Center Phase 2 Study
Bendamustin and bortezomib have been shown to be effective in the treatment of patients with
indolent Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). Both compounds
appear not to be cross-resistant with prior therapy. Therefore, it is of interest to combine
bendamustine and bortezomib in this patient population.
Preliminary results from patients with multiple myeloma showed that the combination of
bendamustine and bortezomib is efficacious and well tolerated. However, there are so far no
data on this combination in patients with NHL or CLL.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Peter R Moosmann, MD PhD
Cantonal Hospital of Aarau